Fertility drugs and risk of ovarian cancer: Dispelling the myth

Current Opinion in Obstetrics and Gynecology

Volumn 20, Issue 3, 2008, Pages 313-319

  Zreik, Tony G ^a,b   Ayoub, Chakib M ^a   Hannoun, Antoine ^a   Karam, Cynthia J ^a   Munkarah, Adnan R ^c  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

Author keywords

Assisted reproductive technologies; Clomiphene citrate; Fertility treatment; Gonadotropins; Infertility; Ovarian cancer

Indexed keywords

CHORIONIC GONADOTROPIN; CLOMIFENE CITRATE; ESTROGEN; FERTILITY PROMOTING AGENT; GONADOTROPIN; HUMAN MENOPAUSAL GONADOTROPIN; MUCIN 1; PROGESTERONE;

ANOVULATION; CANCER RISK; CLINICAL TRIAL; DRUG SAFETY; EMBRYO TRANSFER; ENDOMETRIOSIS; FEMALE INFERTILITY; FERTILIZATION IN VITRO; GONADOTROPIN RELEASE; HIGH RISK PATIENT; HUMAN; INFECTION; LONG TERM CARE; OVARY CANCER; OVARY POLYCYSTIC DISEASE; OVULATION INDUCTION; PATIENT MONITORING; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SIDE EFFECT; TREATMENT OUTCOME;

FEMALE; FERTILITY AGENTS, FEMALE; HUMANS; OVARIAN NEOPLASMS; RETROSPECTIVE STUDIES; RISK;

EID: 43149090269     PISSN: 1040872X     EISSN: None     Source Type: Journal    
DOI: 10.1097/GCO.0b013e3282fdc6c3     Document Type: Review

References (47)

1. United Nations. Universal Declaration of Human Rights, Article 16.1; 1948.
2. European Union. European Convention on Human Rights and Its Five Protocols, Articles 8 and 12.
3. Dill S. Consumer perspectives; Section 4: Social and psychological issues in infertility and ART. In: Vayena E, Rowep PJ, Griffin D, editors. Current Practices and Controversies in Assisted Reproduction. Geneva: World Health Organization; 2002. pp. 255-262.
4. Fathalla MF. Incessant ovulation: a factor in ovarian neoplasia? Lancet 1971; 2:163.
5. Schildkraut JM, Bastos E, Berchuck A. Relationship between lifetime ovulatory cycles and overexpression of mutant p53 in epithelial ovarian cancer. J Natl Cancer Inst 1997; 89:932-938.
6. Terry KL, Titus-Ernstoff L, McKolanis JR, et al. Incessant ovulation, mucin 1 immunity, and risk for ovarian cancer. Cancer Epidemiol Biomarkers Prev 2007; 16:30-35. The authors suggest that immune response may be an additional mediator of the relationship between 'incessant ovulation' and ovarian cancer by lowering protective antibodies against the tumor antigen MUC1.
7. Riman T, Nilsson S, Persson IR. Review of epidemiological evidence for reproductive and hormonal factors in relation to the risk of epithelial ovarian malignancies. Acta Obstet Gynecol Scand 2004; 83:783-795.
8. Hankinson SE, Colditz GA, Hunter DJ, et al. A prospective study of reproductive factors and risk of epithelial ovarian cancer. Cancer 1995; 76:284-290.
9. Tworoger SS, Fairfield KM, Colditz GA, et al. Association of oral contraceptive use, other contraceptive methods, and infertility with ovarian cancer risk. Am J Epidemiol 2007; 166:894-901. The authors observed that the protective effect of long duration of oral contraceptive use waned 20 years after last use. Among other contraceptive methods, most were not associated with risk, with the exception of tubal ligation (inverse association) and intrauterine device (IUD) use (positive association). History of infertility was associated with a modestly increased risk of ovarian cancer. Oral contraceptives are the only known chemoprotective agents for ovarian cancer.
10. Jordan SJ, Green AC, Whiteman DC, et al. Serous ovarian, fallopian tube and primary peritoneal cancers: a comparative epidemiological analysis. Int J Cancer 2007; 122:1598-1603. The authors found remarkably similar risk reductions for serous ovarian cancer and fallopian tube cancer associated with increasing parity, duration of breastfeeding and hormonal contraceptive use. Contrary to one of the prevailing theories of ovarian cancer pathogenesis, the physical effects of ovulation are unlikely to be the initiating event in serous ovarian carcinogenesis.
11. Risch HA, Marrett LD, Howe GR. Parity, contraception, infertility, and the risk of epithelial ovarian cancer. Am J Epidemiol 1994; 140:585-597.
12. Riman T, Dickman PW, Nilsson S, et al. Risk factors for invasive epithelial ovarian cancer: results from a Swedish case-control study. Am J Epidemiol 2002; 156:363-373.
13. Riman T, Dickman PW, Nilsson S, et al. Risk factors for epithelial borderline ovarian tumors: results of a Swedish case-control study. Gynecol Oncol 2001; 83:575-585.
14. Whittemore AS, Harris R, Itnyre J, and the Collaborative Ovarian Cancer Group. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women. Am J Epidemiol 1992; 136:1184-1203.
15. Adami HO, Hsieh CC, Lambe M, et al. Parity, age at first childbirth, and risk of ovarian cancer. Lancet 1994; 344:1250-1254.
16. Brinton LA, Lamb EJ, Moghissi KS, et al. Ovarian cancer risk associated with varying causes of infertility. Fertil Steril 2004; 82:405-414.
17. Melin A, Sparen P, Bergqvist A. The risk of cancer and the role of parity among women with endometriosis. Hum Reprod 2007; 22:3021-3026. This extensive register study has shown an increased risk for different types of malignancies in women hospitalized with the diagnosis of endometriosis, even when controlled for parity. The study clearly shows that parity, or lack of parity, is not the cause of the increased risk of ovarian cancer in women with endometriosis. Thus, other risk factors are certainly involved and need to be studied further.
18. Ness R, Cottreau C. Possible role of ovarian epithelial inflammation in ovarian cancer. J Natl Cancer Inst 1999; 91:1459-1467.
19. Brinton LA, Westhoff CL, Scoccia B, et al. Causes of infertility as predictors of subsequent cancer risk. Epidemiology 2005; 16:500-507.
20. Ness RB, Cramer DW, Goodman MT, et al. Infertility, fertility drugs, and ovarian cancer: a pooled analysis of case-control studies. Am J Epidemiol 2002; 155:217-224.
21. Resta L, Russo S, Colucci GA, Prat J. Morphologic precursors of ovarian epithelial tumors. Obstet Gynecol 1993; 82:81-86.
22. Schildkraut JM, Schwingl PJ, Bastos E, et al. Epithelial ovarian cancer risk among women with polycystic ovary syndrome. Obstet Gynecol 1996; 88:554-559.
23. Venn A, Watson L, Bruinsma F, et al. Risk of cancer after use of fertility drugs with in-vitro fertilisation. Lancet 1999; 354:586-590.
24. Ron E, Lunenfeld B, Menczer J, et al. Cancer incidence in a cohort of infertile women. Am J Epidemiol 1987; 125:780-790.
25. Brinton LA, Melton LJ III, Malkasian GD Jr, et al. Cancer risk after evaluation for infertility. Am J Epidemiol 1989; 129:712-722.
26. Dor J, Lerner-Geva L, Rabinovici J, et al. Cancer incidence in a cohort of infertile women who underwent in vitro fertilization. Fertil Steril 2002; 77:324-327.
27. Dietl J. Ovulation and ovarian cancer. Lancet 1991; 338:445.
28. Goldberg GL, Runowicz CD. Ovarian carcinoma of low malignant potential, infertility, and induction of ovulation: is there a link? Am J Obstet Gynecol 1992; 166:853-854.
29. Nijman HW, Burger CW, Baak JP, et al. Borderline malignancy of the ovary and controlled hyperstimulation, a report of 2 cases. Eur J Cancer 1992; 28A:1971-1973.
30. Mills PK, Riordan DG, Cress RD, Goldsmith DF. Hormone replacement therapy and invasive and borderline epithelial ovarian cancer risk. Cancer Detect Prev 2005; 29:124-132.
31. Chan KK, Wei N, Liu SS, et al. Estrogen receptor subtypes in ovarian cancer: a clinical correlation. Obstet Gynecol 2008; 111:144-151. Estrogen receptor expression in borderline tumors may suggest a role for endocrine therapy in women with this group of tumors. As borderline tumors are generally less responsive to chemotherapy, endocrine therapy would be an attractive alternative. With the knowledge that estrogen receptor expression in borderline tumors is relatively high compared with malignant tumors, endocrine therapy may have an even bigger role in the treatment of these tumors. This potential treatment option will need to be tested by further clinical trials. Overall, understanding the distribution of estrogen receptor may help to explore further the potential of hormonal therapy in ovarian tumors. Further studies would be needed to determine fully the clinical implications of estrogen receptor subtypes in ovarian tumors.
32. Harris R, Whittemore AS, Itnyre J, and the Collaborative Ovarian Cancer Group. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. III. Epithelial tumors of low malignant potential in white women. Am J Epidemiol 1992; 136:1204-1211.
33. Rossing MA, Daling JR, Weiss NS, et al. Ovarian tumors in a cohort of infertile women. N Engl J Med 1994; 331:771-776.
34. Mosgaard BJ, Lidegaard O, Kjaer SK, et al. Ovarian stimulation and borderline ovarian tumors: a case-control study. Fertil Steril 1998; 70:1049-1055.
35. Shushan A, Paltiel O, Iscovich J, et al. Human menopausal gonadotropin and the risk of epithelial ovarian cancer. Fertil Steril 1996; 65:13-18.
36. Parazzini F, Negri E, La Vecchia C, et al. Treatment for fertility and risk of ovarian tumors of borderline malignancy. Gynecol Oncol 1998; 68:226-228.
37. Brinton L. Long-term effects of ovulation-stimulating drugs on cancer risk. Reprod Biomed Online 2007; 15:38-44. Given the recent marketing of fertility drugs and the fact that exposed women are only beginning to reach the cancer age range, further follow-up is necessary. This will also be important to fully resolve effects of exposure to hormones such as gonadotropins, used more recently in conjunction with IVF.
38. Cusidó M, Fábregas R, Pere BS, et al. Ovulation induction treatment and risk of borderline ovarian tumors. Gynecol Endocrinol 2007; 23:373-376. No differences were found between the groups with respect to the type of drug used, whether clomiphene citrate or gonadotropins. Analysis in terms of the number of cycles administered also failed to reveal any differences. This recent series produced no evidence that ovulation induction treatment predisposes women to the development of BOTs.
39. Maltaris T, Boehm D, Dittrich R, et al. Reproduction beyond cancer: a message of hope for young women. Gynecol Oncol 2006; 103:1109-1121.
40. Parazzini F, Pelucchi C, Negri E, et al. Use of fertility drugs and risk of ovarian cancer. Hum Reprod 2001; 16:1372-1375.
41. Brinton LA, Lamb EJ, Moghissi KS, et al. Ovarian cancer risk after the use of ovulation-stimulating drugs. Obstet Gynecol 2004; 103:1194-1203.
42. Mosgaard BJ, Lidegaard O, Kjaer SK, et al. Infertility, fertility drugs, and invasive ovarian cancer: a case-control study. Fertil Steril 1997; 67:1005-1012.
43. Potashnik G, Lerner-Geva L, Genkin L, et al. Fertility drugs and the risk of breast and ovarian cancers: results of a long-term follow-up study. Fertil Steril 1999; 71:853-859.
44. Venn A, Healy D, McLachlan R. Cancer risks associated with the diagnosis of infertility. Best Pract Res Clin Obstet Gynaecol 2003; 17:343-367.
45. Modan B, Ron E, Lerner-Geva L, et al. Cancer incidence in a cohort of infertile women. Am J Epidemiol 1998; 147:1038-1042.
46. Doyle P, Maconochie N, Beral V, et al. Cancer incidence following treatment for infertility at a clinic in the UK. Hum Reprod 2002; 17:2209-2213.
47. Kashyap S, Moher D, Fung MF, Rosenwaks Z. Assisted reproductive technology and the incidence of ovarian cancer: a meta-analysis. Obstet Gynecol 2004; 103:785-794.